KEYTRUDA 25 mg/mL concentrate for solution for infusion, ALIMTA 500 mg powder for concentrate for solution for infusion clinical trials

A phase III trial of a De-escalated Immune-strategy During first-line treAtment in patients with metastatic non-small Cell lung cancer (NSCLC): DIDaC

This study is for people with advanced lung cancer who have responded well to initial immunotherapy. It's looking at whether using less treatment might still be effective, while potentially reducing side effects. Researchers will track how long participants stay well.